Assessment of Quality of Life and Outcomes in Patients With Primary Renal Cell Carcinoma Treated With SBRT

This is a multicenter, single arm phase II study of stereotactic body radiation therapy (SBRT) for patients with medically inoperable primary renal cell carcinoma (RCC).

Trial Details

NCT ID
NCT05023265
Phase
NA
Sponsor
Sunnybrook Health Sciences Centre
Status
RECRUITING
Cancer Type
Kidney Cancer
Interventions
  • Stereotactic body radiotherapy
Locations (sample)
  • Toronto, Ontario, Canada|43.70643,-79.39864

Key Eligibility Criteria

  • Patients ≥18 years old
  • Newly diagnosed RCC by biopsy (preferred) or radiologic evidence of growth on surveillance over two consecutive assessments (6-12 months)
  • Primary lesion \>3 cm, or recurrent lesion following local ablative therapy
  • Medically inoperable or patient who refuses surgery following assessment by experienced urologist, and discussed in a multidisciplinary setting

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →